Medication Quantification Scale Version III: internal validation of detriment weights using a chronic pain population

Area of Science:

• Pharmacology
• Pain Management
• Biostatistics

Background:

• The Medication Quantification Scale (MQS) was developed to quantify drug regimens, with MQS III updated in 2003 using physician-determined detriment weights.
• The MQS has been utilized as a unified outcome measure in clinical practice and research.

Purpose of the Study:

• To internally validate the Medication Quantification Scale III (MQS III) within a chronic pain patient cohort.
• To compare patient-derived MQS III detriment weights with existing physician consensus data.

Main Methods:

• A retrospective chart review of 400 patients from an interdisciplinary outpatient chronic pain clinic was conducted.
• A linear regression equation was developed using composite MQS III scores, followed by Pearson correlation analysis.

Main Results:

• A strong and significant correlation (r = 0.962, P < 0.01) was found between computed regression detriment weights and MQS III detriment weights.
• Detriment weights derived from the chronic pain sample differed from physician consensus in specific drug classes, including SSRIs, Opioid Schedule II, and NSAIDs.

Conclusions:

• The validation indicates the MQS III's utility in chronic pain populations, but reveals discrepancies in detriment weighting for certain medications.
• Periodic resurveys of physicians are essential to update detriment weights, accounting for new drug information and evolving prescribing practices.
• Incorporating patient perspectives on detriment alongside statistical and empirical use patterns is recommended for a comprehensive understanding.